US Stock MarketDetailed Quotes
BIVI BioVie
- 2.800
- +0.090+3.32%
Close Nov 29 13:00 ET
- 2.810
- +0.010+0.34%
Post 17:01 ET
49.75MMarket Cap-551P/E (TTM)
2.820High2.580Low1.10MVolume2.700Open2.710Pre Close2.99MTurnover7.80%Turnover RatioLossP/E (Static)17.77MShares33.10052wk High3.54P/B39.47MFloat Cap1.04052wk Low--Dividend TTM14.10MShs Float460.977Historical High--Div YieldTTM8.86%Amplitude1.040Historical Low2.717Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
BioVie Stock Forum
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
BioVie (NASDAQ: BIVI) announced the acceptance of an abstract detailing their planned Phase 2 trial of bezisterim for Long COVID treatment at the Demystifying Long COVID International Conference in Barcelona. The study, fully funded by the U.S. Department of Defense, will be a double-blind, randomized, placebo-controlled tri...
📊⚡️📊
Biovie’s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BioVie Inc (NASDAQ: BIVI) announced the pricing of a registered direct offering of 1,146,000 shares of common stock at $2.83 per share, aiming to raise approximately $3.2 million in gross proceeds. The offering, priced at-the-market under Nasdaq rules, is expected to close around October 29, 2024. The company plans to use the net proceeds for working capital and general corpo...
No comment yet